Clinical trials: Prostate Cancer Stage
Prostatic Neoplasms
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
- Trial name
- NCT00450008
- Testing
- GM-CSF, thalidomide, docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT03899987
- Testing
- EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer
Docetaxel (Taxotere) is an approved chemotherapeutic drug for the treatment of androgen-independent prostate cancer. The aim of the study is to investigate whether addition of the investigational drug PI-88 will increase the…
- Trial name
- NCT00268593
- Testing
- PI-88, docetaxel, prednisone
- Where
- 8 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Progen Pharmaceuticals
Metastatic Hormone Naive Prostate Cancer
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic…
- Trial name
- UpFrontPSMA (NCT04343885)
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 12 sites in Australia
- Volunteers
- 130 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II…
- Trial name
- NCT00115635
- Testing
- docetaxel, gemcitabine
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Herlev Hospital
Prostate Cancer
Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to <1.0 ng/ml at 3…
- Trial name
- Nexrutine (NCT01705652)
- Testing
- Nexrutine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Trial of eRapa in Prostate Cancer Patients
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance.
- Trial name
- NCT03618355
- Testing
- eRapa (encapsulated rapamycin)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapamycin Holdings, Inc. dba Emtora Biosciences
Metastatic Breast Cancer, Metastatic Colon Cancer
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients
The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours.
- Conditions
- Metastatic Breast Cancer, Metastatic Colon Cancer, Metastatic Prostate Cancer
- Trial name
- NCT02655952
- Testing
- Foxy-5
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 17 people
- Sponsor
- WntResearch AB
Cancer, Breast Cancer
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can prevent recurrence and improve survival in individuals with non-metastatic common tumours.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02804815
- Testing
- Aspirin 100mg, Aspirin 300mg
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 11,000 people
- Sponsor
- University College, London
Prostate Cancer, Radiation Toxicity
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment.
- Conditions
- Prostate Cancer, Radiation Toxicity, Urinary Complication
- Trial name
- NCT05530655
- Testing
- Lisinopril Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Prostate Cancer, Non-Small Cell Lung Cancer
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.
- Conditions
- Prostate Cancer, Non-Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT02538432
- Testing
- RQ-00000007, Gemcitabine
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in men. Patients with recurrent or metastatic prostate cancer are treated with androgen-deprivation therapy, often termed castration therapy.
- Trial name
- NCT01620593
- Testing
- Metformin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance.
- Trial name
- NCT06600698
- Testing
- INM176
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Milton S. Hershey Medical Center
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Prostatic Neoplasms, Prostate Cancer
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
- Trial name
- NCT00383487
- Testing
- Calcitriol, Naproxen-n-butyl nitrate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasm
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor…
- Trial name
- ODYSSEY (NCT00174863)
- Testing
- SR31747A
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 232 people
- Sponsor
- Sanofi
Prostate Cancer
Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00348816
- Testing
- docetaxel, prednisone, Radical prostatectomy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone…
- Trial name
- NCT00193193
- Testing
- Paclitaxel, Estramustine, Carboplatin
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall…
- Trial name
- OMAHA-003 (NCT06136624)
- Testing
- Opevesostat, Abiraterone acetate, Enzalutamide
- Where
- 288 sites in United States, Argentina and 34 more
- Volunteers
- 1,310 people
- Sponsor
- Merck Sharp & Dohme LLC